EP Patent

EP1601325B1 — Antisense oligonucleotides that inhibit expression of hif-1

Assigned to Opus Genetics Inc · Expires 2009-09-02 · 17y expired

What this patent protects

New antisense oligonucleotide compounds, RX-0047 and RX-0149, inhibit expression of HIF-1 and also induce cytotoxicity in several cancer cell lines.

USPTO Abstract

New antisense oligonucleotide compounds, RX-0047 and RX-0149, inhibit expression of HIF-1 and also induce cytotoxicity in several cancer cell lines.

Drugs covered by this patent

Patent Metadata

Patent number
EP1601325B1
Jurisdiction
EP
Classification
—
Expires
2009-09-02
Drug substance claim
No
Drug product claim
No
Assignee
Opus Genetics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.